Cardio protective effect of nicorandil in reperfusion injury among patients undergoing primary percutaneous coronary

Related Experiment Video

Updated: Aug 12, 2025

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.3K

Maria Ilyas1, Mudassar Noor2, Hamid Sharif Khan3

  • 1Dr. Maria Ilyas, MBBS., Department of Pharmacology, Army Medical College, National University of Medical Sciences, Rawalpindi, Pakistan.

Pakistan Journal of Medical Sciences
|January 25, 2023
PubMed

Insights

Nicorandil effectively prevents reperfusion injury in ST-elevated myocardial infarction patients undergoing primary percutaneous coronary intervention. This reduces complications and mortality, highlighting nicorandil

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Reperfusion injury is a significant complication following primary percutaneous coronary intervention (PCI) for ST-elevated myocardial infarction (STEMI).
  • The
  • no-reflow
  • phenomenon contributes to adverse outcomes.

Purpose of the Study:

  • To evaluate the efficacy of nicorandil in preventing reperfusion injury during primary PCI.
  • To assess the impact of nicorandil on Thrombolysis in Myocardial Infarction (TIMI) flow grade scoring.

Main Methods:

  • A randomized controlled study involving 140 STEMI patients undergoing primary PCI.
  • Patients were divided into two groups: a control group receiving the standard acute coronary syndrome (ACS) protocol and an experimental group receiving nicorandil plus the ACS protocol.
  • TIMI flow grade scoring was used to assess reperfusion during PCI.

Main Results:

  • The nicorandil group showed a significantly higher incidence of TIMI Grade-3 flow compared to the control group (p=0.001).
  • This indicates a reduced rate of the no-reflow phenomenon in patients treated with nicorandil.
  • Nicorandil administration prior to primary PCI demonstrated superior outcomes.

Conclusions:

  • Nicorandil is effective in preventing reperfusion injury in STEMI patients undergoing primary PCI.
  • The prophylactic use of nicorandil reduces post-PCI complications and mortality.
  • Nicorandil plays a significant cardio-protective role in managing myocardial infarction.
Abstract

Keywords:
Cardio protective agentsNicorandilPercutaneous coronary interventionmyocardial reperfusion injury

More Related Videos

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

6.1K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.6K

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
20
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
22
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
680
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
612
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
61